Literature DB >> 25056241

A retrospective study of prognostic factors in patients with interstitial pneumonia receiving long-term oxygen therapy.

Masayoshi Higashiguchi1, Takashi Kijima, Hiromitsu Sumikawa, Osamu Honda, Toshiyuki Minami, Haruhiko Hirata, Koji Inoue, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Noriyuki Tomiyama, Atsushi Kumanogoh.   

Abstract

PURPOSE: We retrospectively analyzed patients with clinically diagnosed interstitial pneumonia to investigate the factors which contribute to the difference in prognosis from the initiation of long-term oxygen therapy (LTOT) among subtypes.
METHODS: Seventy-six patients with clinically diagnosed idiopathic interstitial pneumonia (IIP; n = 49) or interstitial pneumonia associated with collagen vascular disease (CVD-IP; n = 27) in whom LTOT was initiated in our facility from January 1999 to December 2012 were analyzed.
RESULTS: Patients with CVD-IP had significantly longer survival time from the initiation of LTOT than those with IIP with the median survival of 51.7 months versus 18.8 months, respectively. The 1-year survival rate was 92.4% for patients with CVD-IP versus 76.5% for those with IIP, and 2-year survival was 88.6 versus 36.0%, respectively. The patterns classified with high-resolution computed tomography (HRCT) were not associated with prognosis. The association between pulmonary hypertension and prognosis was unclear. In results of the multivariate Cox analysis which included factors demonstrating p < 0.1 in the univariate Cox analysis, male gender, low body mass index, and the absence of collagen vascular disease (CVD) were significantly associated with poor prognosis.
CONCLUSIONS: After the initiation of LTOT, patients with IIP had poor prognosis regardless of the patterns classified with HRCT, while those with CVD-IP survived longer. Male gender, low body mass index, and the absence of CVD were the independent negative prognostic factors in patients with interstitial pneumonia receiving LTOT.

Entities:  

Mesh:

Year:  2014        PMID: 25056241     DOI: 10.1007/s00408-014-9623-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  27 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

3.  Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

Authors:  Marco Mura; Maria A Porretta; Elena Bargagli; Gianluigi Sergiacomi; Maurizio Zompatori; Nicola Sverzellati; Amedeo Taglieri; Fabrizio Mezzasalma; Paola Rottoli; Cesare Saltini; Paola Rogliani
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

Review 4.  Significance of connective tissue diseases features in pulmonary fibrosis.

Authors:  Vincent Cottin
Journal:  Eur Respir Rev       Date:  2013-09-01

5.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

6.  Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

Authors:  B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

7.  Body mass index and mortality in patients with idiopathic pulmonary fibrosis.

Authors:  Mazen Alakhras; Paul A Decker; Hassan F Nadrous; Maria Collazo-Clavell; Jay H Ryu
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

8.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

9.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

10.  Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival.

Authors:  Hiromitsu Sumikawa; Takeshi Johkoh; Thomas V Colby; Kazuya Ichikado; Moritaka Suga; Hiroyuki Taniguchi; Yasuhiro Kondoh; Takashi Ogura; Hiroaki Arakawa; Kiminori Fujimoto; Atsuo Inoue; Naoki Mihara; Osamu Honda; Noriyuki Tomiyama; Hironobu Nakamura; Nestor L Müller
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

View more
  1 in total

1.  Risk factors for pneumonia among patients with Parkinson's disease: a Taiwan nationwide population-based study.

Authors:  Yang-Pei Chang; Chih-Jen Yang; Kai-Fang Hu; A-Ching Chao; Yu-Han Chang; Kun-Pin Hsieh; Jui-Hsiu Tsai; Pei-Shan Ho; Shen-Yang Lim
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-27       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.